# The True Cost of Poor-Quality Specimens

Poor-quality specimens result in high failure rates, costing you time and money.

According to a US survey of National Cancer Institute (NCI) funded cancer researchers, lack of quality biospecimens resulted in 60% of researchers questioning their findings and 81% limiting the scope of their work.<sup>1</sup>

#### What is poor specimen quality costing you?



#### **ADD IT UP:**

There can be up to \$30K in hidden costs due to biospecimen failures.

## Avoid These Hidden Costs by Using a High-Quality Provider

The ASTERAND® portfolio is well established for its unparalleled quality. Our brand is synonymous with excellence, assuring clients of the high standards surrounding our human tissue specimens. We ensure reliable, reproducible results by implementing consistent collection methods and stringent quality control processes. By choosing ASTERAND®, you not only receive top-notch quality but also save valuable time by avoiding the need to repeat assays caused by specimen failure.



<sup>&</sup>lt;sup>1</sup> Assessing the need for a standardized cancer Human Biobank (caHUB): findings from a national survey with cancer researchers. Massett HA1, Atkinson NL, Weber D, Myles R, Ryan C, Grady M, Compton C.



<sup>&</sup>lt;sup>2</sup> Simoens et al R&D Costs of New Medicines: A Landscape Analysis Front. Med., 26 October 2021

# Our Specimens Will Work the 1st Time, Every Time

ASTERAND® Human Tissue samples have had a <1% reported issue rate for over 20 years and 1,000,000 processed samples.

#### Before You Get ASTERAND® Human Tissue Specimens, They Undergo:

#### **Histology Quality Control**

- Size Criteria: <3mm tissue block depth impacts the ability to section
- Specimen Integrity Criteria: Free from air bubbles, discoloration, cracking, contamination
- Quality Score: Perform additional processing or discard/quarantine poor quality samples

#### Pathology and Data Integrity Review

- Pathology Confirmation: Diagnosis, tumor grade, tumor stage
- All specimens subject to clinical data case review
- Those with discrepancies are held in quarantine until resolution occurs

#### It's More Than Just a Specimen:

- Documented Patient Consent & IRB Approval for Broad Research Use
- External Quality Assurance through Accreditations
- Annual Auditing of Clinical Sites
- Consistent Specimen Collection SOPs
- Standardized Data Collection (OpenClinica)
- Secondary Pathologist Review
- Specimen QC through Histology Assessment





### **How We Compare:**

	BioIVT (ELITE)	BioIVT (Accredited)	Other Providers
Data Set	<ul> <li>Aperio H&amp;E Slide Image access</li> <li>17 Socio-demographic data points</li> <li>&gt;200 data points</li> <li>Available Outcomes date (select cohorts)</li> <li>Format: FFPE/Fresh Frozen with matched biofluids</li> </ul>	<ul> <li>Aperio H&amp;E Slide Image access</li> <li>6 Essential Socio-demographic data points and clinical data points</li> <li>All BioIVT QC data points including percent tumor (&gt;25% guaranteed)</li> <li>Format: FFPE</li> </ul>	<ul> <li>Limited Aperio H&amp;E Slide Images</li> <li>Variable Socio-demographic data, frequently limited</li> <li>Variable clinical data points, frequently limited or non-existent</li> </ul>
Quality Control	<ul> <li>Secondary Board-certified pathology review to confirm diagnosis</li> <li>RNA Integrity number (RIN) for all Fresh Frozen</li> <li>DV200 (select lots with NGS)</li> <li>Histology QC</li> </ul>	<ul> <li>Secondary Board-certified pathology review to confirm diagnosis</li> <li>Histology QC</li> </ul>	Many lack independent QC
Regulatory	<ul><li>Consent Status &amp; Year</li><li>Access to blinded IRB and ICF prior to purchase</li></ul>	<ul><li>Consent Status &amp; Year</li><li>Access to blinded IRB and ICF prior to purchase</li></ul>	Variable details

Visit BioIVT.com to Learn More & Speak with Our Experts

